awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q47259944-16E451F6-3AB2-4D5A-98F9-7C4E80D0E289
Q47259944-16E451F6-3AB2-4D5A-98F9-7C4E80D0E289
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47259944-16E451F6-3AB2-4D5A-98F9-7C4E80D0E289
Estimating the returns to United Kingdom publicly funded musculoskeletal disease research in terms of net value of improved health outcomes.
P2860
Q47259944-16E451F6-3AB2-4D5A-98F9-7C4E80D0E289
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47259944-16E451F6-3AB2-4D5A-98F9-7C4E80D0E289
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
b5c9b84627bf4aefec23fa4ef99f3c22fe256540
P2860
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-mo